# Biolinq

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biolinq

- Industry: Medical Devices & Equipment
- Headquarters: San Diego, US
- Website: www.biolinq.com
- Total disclosed funding: $173M
- Latest round: Series C (Mar 7, 2025)
- Investors on record: 20

## About

Based in California, US, Biolinq Inc. provides an electrochemical sensor for measuring metabolic health. In April 2024, the firm raised USD 58 million in venture funding led by returning investor Alpha Wave Global, with participation from investor Pegasus Tech Ventures. Returning investors RiverVest Ventures, AXA IM Alts, Global Health Impact Fund, Aphelion Capital, Senvest Management, Features Capital, and Taisho Pharmaceutical Co., Ltd. also participated in the round. In March 2025, Biolinq Inc raised USD 100 million in series C led by new investor Alpha Wave Global, with participation from returning investors Aphelion Capital, AXA IM Alts, Features Capital, Hikma Ventures, LifeSci Venture Partners, M Ventures, RiverVest Ventures, and Taisho Pharmaceutical Co., Ltd. Other unspecified investors also participated in the round. As of 2024, the company is headed by its CEO Rich Yang. Biolinq's product is a biowearable platform that utilizes a multi-sensor array to detect and monitor various metabolic analytes, such as glucose, directly through the skin. This platform offers continuous, real-time feedback on metabolic health, using an array of ultra-small, electrochemical sensors.

## Funding rounds

- Series C, Mar 7, 2025, $100M — RiverVest Ventures Partners, Aphelion Capital, AXA Investment Managers, Alpha Wave Global, Hikma Ventures, M Ventures, Taisho Pharmaceutical Co., Ltd., Features Capital
- Series B, Sep 2, 2021, $62M — RiverVest Ventures Partners, Aphelion Capital, AXA IM Alts, Senvest Management, Alpha Wave Global, The Broe Group, Ascensia Diabetes Care Holdings AG, Hikma Ventures, JDRF T1D Fund, M Ventures, Global Health Impact Funds, Able Partners, Longevity Vision Holding, Taisho Pharmaceutical Co., Ltd., T&W Holding
- Series A, Mar 13, 2019, $3M — Aphelion Capital, JDRF T1D Fund, LifeSci Partners
- Series A, Nov 14, 2017, $8.1M — Three Leaf Ventures, Grey Sky Venture Partners, Hikma Ventures, LifeSci Partners

## Investors

- Three Leaf Ventures (https://capitalatlas.ai/funds/three-leaf-ventures) — Series A
- Grey Sky Venture Partners (https://capitalatlas.ai/funds/grey-sky-venture-partners) — Series A
- Hikma Ventures (https://capitalatlas.ai/funds/hikma-ventures) — Series A, Series B, Series C
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series A
- Aphelion Capital (https://capitalatlas.ai/funds/aphelion-capital) — Series A, Series B, Series C
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series A, Series B
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series B, Series C
- AXA IM Alts — Series B
- Senvest Management — Series B
- Alpha Wave Global (https://capitalatlas.ai/funds/alpha-wave-global) — Series B, Series C
- The Broe Group (https://capitalatlas.ai/funds/the-broe-group) — Series B
- Ascensia Diabetes Care Holdings AG — Series B
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series B, Series C
- Global Health Impact Funds (https://capitalatlas.ai/funds/global-health-impact-funds) — Series B
- Able Partners (https://capitalatlas.ai/funds/able-partners) — Series B
- Longevity Vision Holding (https://capitalatlas.ai/funds/longevity-vision-holding) — Series B
- Taisho Pharmaceutical Co., Ltd. — Series B, Series C
- T&W Holding — Series B
- AXA Investment Managers — Series C
- Features Capital (https://capitalatlas.ai/funds/features-capital) — Series C